NCT02340481 arm group b9a41088c3f39a657ebaab38f4089a0c [clinicaltrials_resource:NCT02340481/arm-group/b9a41088c3f39a657ebaab38f4089a0c]
Loperamide hydrochloride placebo capsule [clinicaltrials_resource:24b3723158c456d873958d781741e410]Loperamide hydrochloride + simethicone chewable tablet [clinicaltrials_resource:3fb4530de3906ff6b5c82e3426728f55]Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence [clinicaltrials:NCT02340481]
arm group [clinicaltrials_vocabulary:arm-group]
NCT02340481 arm group b9a41088c3f39a657ebaab38f4089a0c [clinicaltrials_resource:NCT02340481/arm-group/b9a41088c3f39a657ebaab38f4089a0c]
Bio2RDF identifier
NCT02340481/arm-group/b9a41088c3f39a657ebaab38f4089a0c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a41088c3f39a657ebaab38f4089a0c
description [clinicaltrials_vocabulary:description]
Participant will take 2 lopera ...... 4-hour period) up to 48 hours.
identifier
clinicaltrials_resource:NCT02340481/arm-group/b9a41088c3f39a657ebaab38f4089a0c
title
NCT02340481 arm group b9a41088c3f39a657ebaab38f4089a0c
@en
type
label
NCT02340481 arm group b9a41088 ...... 41088c3f39a657ebaab38f4089a0c]
@en